title: Patients' perceived benefit from and satisfaction with asthma-related pharmacy services.
abstract: OBJECTIVE
  To determine whether patients targeted to receive intervention from an asthma management program reported receiving more services and had greater perceived benefit and satisfaction with those services compared with asthma patients not targeted by the program.
  
  
  METHODS
  Mailed survey.
  
  
  METHODS
  Community pharmacy.
  
  
  METHODS
  471 community-based patients receiving asthma medications from 44 intervention pharmacies and 1,164 patients from 46 usual care (control) pharmacies.
  
  
  METHODS
  Five-point agreement scale measuring asthma services received, perceived value of the services, and satisfaction.
  
  
  RESULTS
  Usable surveys were received from 39.0% of intervention patients and 42.4% of controls. There were no statistically significant differences between groups in the frequency of provision of listed services. Approximately 60% of respondents from both groups received written materials on asthma medications and 54% received inhaler counseling; both were rated high for perceived benefit. Fewer than 20% reported being counseled about asthma triggers. Fewer than 5% reported pharmacists talking to physicians on their behalf. General satisfaction with pharmacy services was high (78.2% agree or strongly agree), but not statistically different between groups. More than 65% believed that pharmacists spend enough time counseling patients. Several comments indicated that patients did not expect or ask for information because they were unaware that services were available and/or they had already been counseled by their physician. Responses to the statement "my asthma is better controlled because of help given to me by the pharmacist" were equivocal and not different between groups.
  
  
  CONCLUSIONS
  Overall, there were few differences between groups. General satisfaction with pharmacy services is high, but patients' perceived benefit and satisfaction with cognitive services is lower. Increased public awareness of pharmacists' capabilities and a more proactive approach to providing cognitive services is needed.
authors.affiliation: College of Pharmacy, Oregon State University, Corvallis 97331, USA. wayne.kradjan@orst.edu
authors.forename: W A
authors.initials: WA
authors.lastname: Kradjan
authors.forename: R
authors.initials: R
authors.lastname: Schulz
authors.forename: D B
authors.initials: DB
authors.lastname: Christensen
authors.forename: A
authors.initials: A
authors.lastname: Stergachis
authors.forename: S
authors.initials: S
authors.lastname: Sullivan
authors.forename: D S
authors.initials: DS
authors.lastname: Fullerton
authors.forename: L
authors.initials: L
authors.lastname: Sturm
authors.forename: G
authors.initials: G
authors.lastname: Schneider
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000523:psychology*; D006801:Humans; D010353:Patient Education as Topic; D017060:Patient Satisfaction / Q000706:statistics & numerical data*; D010361:Patients; D010593:Pharmaceutical Services / Q000706:statistics & numerical data*; D011795:Surveys and Questionnaires
chemical_list: D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents